Last updated: 2026-10-13 07:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CareDx, Inc. (CDNA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $63.21, with a market capitalisation of $3.29B and a P/E ratio of 29.42. Over the past 52 weeks, its price has ranged from $14.03 to $72.51. This page covers its latest market performance, valuation, price trends and company information.
$3.29B | |
$63.28 | |
$99.83 | |
$0.76 | |
$63.67 | |
770.59K | |
1.31M | |
29.42 | |
$72.51 | |
$14.03 | |
-- | |
-- |
CareDx, Inc. (CDNA) last closed at $63.67 as of 2026-10-12 23:43:00, unchanged from the previous close of $63.67.
During the latest regular trading session, CDNA traded between $0.76 and $99.83, with a volume of 770.59K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, CareDx, Inc. (CDNA) moved from $67.15 to $63.21, representing a decline of 5.87% ($3.95).
The stock traded between $61.19 and $72.51 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.55 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.1%
CDNA is currently trading at $63.21, placing it 84.1% of the way from its 52-week low of $14.03 to its 52-week high of $72.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 765 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CareDx, Inc. (CDNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.